@article{e9192f98a6ce4982b21be5b41804dde3,
title = "Therapies for tuberculosis and AIDS: Myeloid-derived suppressor cells in focus",
abstract = "The critical role of suppressive myeloid cells in immune regulation has come to the forefront in cancer research, with myeloidderived suppressor cells (MDSCs) as a main oncology immunotherapeutic target. Recent improvement and standardization of criteria classifying tumor-induced MDSCs have led to unified descriptions and also promoted MDSC research in tuberculosis (TB) and AIDS. Despite convincing evidence on the induction of MDSCs by pathogen-derived molecules and inflammatory mediators in TB and AIDS, very little attention has been given to their therapeutic modulation or roles in vaccination in these diseases. Clinical manifestations in TB are consequences of complex host-pathogen interactions and are substantially affected by HIV infection. Here we summarize the current understanding and knowledge gaps regarding the role of MDSCs in HIV and Mycobacterium tuberculosis (co)infections. We discuss key scientific priorities to enable application of this knowledge to the development of novel strategies to improve vaccine efficacy and/or implementation of enhanced treatment approaches. Building on recent findings and potential for cross-fertilization between oncology and infection biology, we highlight current challenges and untapped opportunities for translating new advances in MDSC research into clinical applications for TB and AIDS.",
author = "Anca Dorhoi and Kotz{\'e}, {Leigh A.} and Berzofsky, {Jay A.} and Yongjun Sui and Gabrilovich, {Dmitry I.} and Ankita Garg and Richard Hafner and Khader, {Shabaana A.} and Schaible, {Ulrich E.} and Kaufmann, {Stefan H.E.} and Gerhard Walzl and Lutz, {Manfred B.} and Mahon, {Robert N.} and Suzanne Ostrand-Rosenberg and William Bishai and {Du Plessis}, Nelita",
note = "Funding Information: The authors thank Helga Ke{\ss}ler for editorial assistance, Michael R. Knittler for assistance with the graphics work, and our fellow workshop presenters, Evgeniy Eruslanov, Anne Goldfeld, Tim Greten, Tom Ottenhoff, and Ethan Shevach, for their insights and lively discussion. This work has been supported by the Division of AIDS, National Institute of Allergy and Infectious Diseases, NIH, Department of Health and Human Services (contract HHSN272201600001G–Research Support Services for the Division of AIDS support for this publication and the workshop Suppressor Cells and TB/HIV: What Is Known and What Can Be Learned?, January 2019). WB gratefully acknowledges the support of NIH grants AI37856, HL133190, and AI130595. AG is funded by NIH AI127132 and the University of Georgia Research Foundation. NDP is sponsored by the European and Developing Countries Clinical Trials Partnership (CDF1546). Publisher Copyright: {\textcopyright} 2020, American Society for Clinical Investigation.",
year = "2020",
month = jun,
day = "1",
doi = "10.1172/JCI136288",
language = "English",
volume = "130",
pages = "2789--2799",
journal = "Journal of Clinical Investigation",
issn = "0021-9738",
number = "6",
}